Get Pro-Level Earnings Insights Before the Market Moves The trial demonstrated that Sarclisa SC, in combination with pomalidomide and dexamethasone ... Sarclisa SC formulations across different ...

subcutaneous formulation via an on-body delivery system (OBDS) versus weight-based dosed Sarclisa IV in combination with pomalidomide and dexamethasone (Pd) in adult patients with relapsed or ...

Sanofi SNY announced that the phase III IRAKLIA study, which evaluated a fixed-dose subcutaneous (SC) formulation of its blood cancer drug, Sarclisa (isatuximab) for the treatment of relapsed or ...

Data from the study showed that the new SC formulation of Sarclisa in combination with Bristol Myers’ BMY Pomalyst (pomalidomide) and dexamethasone (Pd) when administered through an on-body ...

Data from the study showed that the new SC formulation of Sarclisa in combination with Bristol Myers’ BMY Pomalyst (pomalidomide) and dexamethasone (Pd) when administered through an on-body ...

On Thursday, Sanofi SA (NASDAQ:SNY) released results from the IRAKLIA phase 3 study evaluating the non-inferiority of Sarclisa (isatuximab) subcutaneous formulation via an on-body delivery system ...

The drug is also approved in combination with Amgen’s Kyprolis (carfilzomib) and dexamethasone for treating patients with R/R MM who have received 1–3 prior lines of therapy.